" The aim of the current clinical study was to assess if the Voyager is a safe and feasible treatment for rGBM. In contrast to the first study in which patients were treated with Voyager as monotherapy or in combination with standard chemotherapeutic agents [9], all patients in the current study received treatment with Voyager alone. Safety results were similar in both studies." {Credits 1} {Credits 1} 🎪 Murphy, M., Dowling, A., Thien, C., Priest, E., Morgan Murray, D., & Kesari, S. (2019). A feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma in Australia. CNS oncology, 8(1), CNS31. © 2019 Nativis, Inc. This work is licensed under the CC Attribution-NonCommercial-NoDerivatives 4.0 Unported License. |
Last modified on 22-Jan-20 |